Showing results (331-340 of 351) with videos related to

Sort By:
Pageof 36
Leukemia|March 22, 2017
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring SystemM G Della Porta, C H Jackson, E P Alessandrino, et al.
Blood|May 10, 2024
Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?Christof Scheid, Diderik-Jan Eikema, Michel van Gelder, et al.
Transplantation and Cellular Therapy|November 24, 2021
GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and CriticismsMichele Malagola, Nicola Polverelli, Vicky Rubini, et al.
Blood Advances|February 10, 2025
Posttransplant cyclophosphamide as GVHD prophylaxis in patients receiving mismatched unrelated HCT: the PHYLOS trialAnna Maria Raiola, Benedetto Bruno, Antonio Maria Risitano, et al.
Transplantation Direct|February 27, 2023
Busulfan or Treosulfan Conditioning Platform for Allogeneic Stem Cell Transplantation in Patients Aged >60 Y With Acute Myeloid Leukemia/Myelodysplastic Syndrome: A Subanalysis of the GITMO AlloEld StudyMichele Malagola, Nicola Polverelli, Massimo Martino, et al.
The Lancet. Haematology|October 28, 2023
Germline predisposition traits in allogeneic hematopoietic stem-cell transplantation for myelodysplastic syndromes: a survey-based study and position paper on behalf of the Chronic Malignancies Working Party of the EBMTCarmelo Gurnari, Marie Robin, Lucy A Godley, et al.
Blood|May 7, 2025
BLAST: A Globally Applicable and Molecularly Versatile Survival Model for Chronic Myelomonocytic LeukemiaAyalew Tefferi, Saubia Fathima, Maymona Abdelmagid, et al.
Bone Marrow Transplantation|October 31, 2017
'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO)L Giaccone, G Mancini, N Mordini, et al.
Bone Marrow Transplantation|April 13, 2022
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01Francesca Bonifazi, Chiara Pavoni, Jacopo Peccatori, et al.
Blood|June 10, 2023
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendationsKai Rejeski, Marion Subklewe, Mahmoud Aljurf, et al.
Pageof 36